Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.

@article{Casagrande2014PreclinicalAO,
  title={Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.},
  author={Naike Casagrande and Marta Celegato and Cinzia Borghese and Maurizio Mongiat and Alfonso Colombatti and Donatella Aldinucci},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 21},
  pages={5496-506}
}
PURPOSE Cisplatin and its platinum derivatives are first-line chemotherapeutic agents in the treatment of ovarian cancer; however, treatment is associated with tumor resistance and significant toxicity. Here we investigated the antitumoral activity of lipoplatin, one of the most promising liposomal platinum drug formulations under clinical investigation. EXPERIMENTAL DESIGN In vitro effects of lipoplatin were tested on a panel of ovarian cancer cell lines, sensitive and resistant to cisplatin… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer

  • N Casagrande, M De Paoli, M Celegato, C Borghese, M Mongiat, A Colombatti
  • Gynecol Oncol 2013;131:744–52
  • 2013
Highly Influential
7 Excerpts

Similar Papers

Loading similar papers…